Want to see IBIO full AI Analyst Report?
IBIO Stock Chart & Stats
$1.47
$0.03(2.14%)
At close: 4:00 PM EDT
$1.47
$0.03(2.14%)
Day’s Range― - ―
52-Week Range$0.73 - $3.82
Previous CloseN/A
Volume1.21M
Average Volume (3M)716.05K
Market Cap
$46.25M
Enterprise Value$11.63M
Total Cash (Recent Filing)$88.04M
Total Debt (Recent Filing)$2.20M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 17, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding60,853,560
10 Day Avg. Volume1,128,185
30 Day Avg. Volume716,049
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.12
Price to Sales (P/S)1821.05
P/FCF Ratio-7.65
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue116.31
Enterprise Value/Gross Profit116.31
Enterprise Value/Ebitda-0.36
Forecast
1Y Price Target
$6.00Price Target Upside308.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$25.00K
Bulls Say, Bears Say
Bulls Say
Promising IBIO-610 Preclinical ProfileThe preclinical findings suggest IBIO-610 may address an important limitation of obesity treatments by improving muscle preservation while supporting durable weight reduction. The observed Activin E suppression and potentially infrequent dosing could strengthen differentiation if replicated in human studies.
Low Current LeverageVery low leverage reduces near-term balance-sheet pressure and avoids substantial interest or refinancing burdens while the pipeline advances. This gives management greater flexibility to allocate capital toward research and clinical preparation, although it does not offset the company’s operating losses.
Strengthened Clinical LeadershipAdding an experienced endocrinology and biopharmaceutical executive can improve clinical planning, regulatory execution, and translation of obesity research into human studies. Her background supports the company’s transition toward clinical development and may help advance multiple cardiometabolic programs.
Bears Say
Minimal And Declining RevenueThe very small and declining revenue base shows that iBio has not yet established meaningful commercial traction. With limited operating revenue to fund research, the company remains dependent on external financing and successful pipeline development to build a sustainable business model.
Deep Ongoing LossesLarge operating and net losses indicate that current expenses substantially exceed the company’s revenue-generating capacity. Persistent negative profitability limits internal funding for development, increases dependence on capital markets, and leaves future earnings power highly contingent on clinical and commercial success.
Persistent Cash Consumption And Financing DependenceOngoing negative operating and free cash flow means iBio must continue funding research and corporate activities without self-generated cash. The company’s reliance on capital markets, alongside expanded share authorization, creates a durable risk of financing pressure and potential shareholder dilution.
Ibio News
IBIO FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was $0.73 and its highest was $3.82 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is $46.25M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is Nov 17, 2026 which is in 27 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on Aug 28, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.069 by $0.019.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.07.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 60,853,560 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.069. Following the earnings report the stock price went down -2.857%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in IBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (308.16% Upside)
$6.00 (308.16% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.58%
12-Months-Change
Fundamentals
Return on Equity
-47.92%
Trailing 12-Months
Asset Growth
327.47%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ibio Inc
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
IBIO Stock 12 Month Forecast
Average Price Target
$6.00
▲(308.16% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―
Ownership Overview
0.50% Insiders
2.14% Mutual Funds
<0.01% Other Institutional Investors
93.75% Public Companies and
Individual Investors